Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 6189

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6189

License Grant
The Company hereby grants the Spanish Licensee an exclusive license to use and sell Licensed Product in Spain and Portugal, including the right to sublicense Licensed Product in Spain, which includes its right to use and sell Licensed Product in Spain and Portugal.
License Property
Licensed Product shall mean the patented active ingredient (+)-calanolide A.  Calanolides is an antiviral compounds, compositions used in the treatment of viral infection, viral-related infection or viral-related disease in humans.
Field of Use
Field of use relates to the medical industry.

IPSCIO Record ID: 5118

License Grant
Licensor, government organization, desires to transfer these inventions to the private sector through commercialization licenses to facilitate the commercial development of products and processes for public use and benefit.
Licensee desires to acquire commercialization rights to certain of these inventions in order to develop processes, methods, or marketable products for public use and benefit.
License Property
USPA SN 07/861,249 'Calanolides, Novel Antiviral Compounds, Compositions and Uses Thereof'

USPA SN 08/065,618 (CIP of SN 07/861,249) 'Calanolides, Novel Antiviral Compounds, Compositions and Uses Thereof'

Field of Use
Licensed Fields of Use Treatment of viral infection, viral-related infection or viral-related disease in humans.

IPSCIO Record ID: 5707

License Grant
Licensor, government public health organization, hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license to Licensee under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, and to sell and have sold any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
USPA SN 07/861,249 Calanolides, Novel Antiviral Compounds, Compositions and Uses Thereof.  USPA SN 08/065,618 (CIP of SN 07/861,249) Calanolides, Novel Antiviral Compounds, Compositions and Uses Thereof.
Field of Use
Licensed Fields of Use Treatment of viral infection, viral-related infection or viral-related disease in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.